Last reviewed · How we verify
MOR03087 phase 1 dose escalation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MOR03087 phase 1 dose escalation (MOR03087 phase 1 dose escalation) — MorphoSys AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MOR03087 phase 1 dose escalation TARGET | MOR03087 phase 1 dose escalation | MorphoSys AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MOR03087 phase 1 dose escalation CI watch — RSS
- MOR03087 phase 1 dose escalation CI watch — Atom
- MOR03087 phase 1 dose escalation CI watch — JSON
- MOR03087 phase 1 dose escalation alone — RSS
Cite this brief
Drug Landscape (2026). MOR03087 phase 1 dose escalation — Competitive Intelligence Brief. https://druglandscape.com/ci/mor03087-phase-1-dose-escalation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing